Health News Archive - April 10, 2009
New research by economics and psychology researchers at the University of Warwick has found that promotion on average produces 10% more mental strain and gives up to 20% less time to visit the Doctors.
A study published tomorrow (10 April) in Science examines a key player in conditions such as cancer, inflammatory bowel disease, rheumatoid arthritis and asthma and has shown that cells use a sophisticated communication system to coordinate responses to infection and maintain inflammation in the body.
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.
For years, microbiologist Stephen Beverley, Ph.D., has tried to get the disease-causing parasite Leishmania in the mood for love.
Chewing gum regularly may reduce sweet cravings and hunger, new research suggests.
It may not be worth it for patients with early bladder cancer to get more intensive therapy for their disease.
Scientists may have a better idea why obese people develop insulin resistance, a precursor to diabetes.
The first antiretroviral treatments appeared in 1996. Since then, new and better drugs have been discovered that have almost turned AIDS into a chronic disease. Nevertheless, there is still room to improve the performance of the the therapeutic strategies used in clinical practice.
Scientists at Burnham Institute for Medical Research (Burnham) and the University of California San Diego (UC San Diego) School of Medicine have demonstrated in mice that transplanted pancreatic precursor cells are protected from the immune system when encapsulated in polytetrafluorethylene (PTFE).
EXTON, Pa., April 10 /PRNewswire/ -- On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva (efalizumab, marketed by Genentech/Roche and Xoma) from the US market.
- A person in a secondary role, specifically the second most important character (after the protagonist).